Star Scientific, Inc. reported financial results for the first quarter ended March 31, 2013. For the quarter, the company reported net sales of $2.5 million compared with $1.1 million for the same period in 2012. The increase of 127% was attributable exclusively to increased Anatabloc(R) sales volume. The net loss was $8.2 million compared with a $5.2 million net loss for the same period in 2012. The increased loss for the first quarter was primarily attributable to increases in sales and marketing costs, legal expenses, and research and development costs. Sales and marketing costs increased as the company expanded promotion of its Anatabloc(R) dietary supplement product.

Robbins Arroyo LLP announced that the firm filed a federal securities fraud class action complaint on May 7, 2013, against Star Scientific, Inc. in the U.S. District Court for the Eastern District of Virginia on behalf of all persons who purchased or otherwise acquired Star Scientific stock between October 31, 2011 and March 18, 2013, inclusive, against the company and certain of its officers and directors for violations of the Securities Exchange Act of 1934. Star Scientific and its operating subsidiaries manufacture, distribute, and sell consumer products and dietary supplements. The complaint alleges that defendants made materially false and misleading statements during the Class Period in press releases, analyst conference calls, and filings with the U.S. Securities and Exchange Commission. Specifically, the complaint alleges that Star Scientific misled investors about the true nature and extent of Johns Hopkins University's involvement in the clinical testing of the company's nutritional supplement, Anatabine; concealed the true nature and extent of its liquidity condition; engaged in improper private placement and related-party transactions since at least 2006; and delayed disclosure of the fact that the company had received subpoenas from the U.S. Attorney's office investigating potential securities fraud. As a result of defendants' false statements, Star Scientific's stock traded at artificially inflated prices during the Class Period, reaching a high of $4.99 per share on July 3, 2012.

Star Scientific, Inc. announced that the company's second cosmetic product, Anatabloc(R) Revitalizing Facial Serum, is now available for sale on GNC's website. The Anatabloc(R) serum is specifically formulated to penetrate the skin and target specific skin concerns, including, wrinkles, firming, age spots, and discolorations. Regular application of the serum can significantly improve the appearance of the skin. The serum is designed to be used prior to the application of Anatabloc(R) Rare Cellular Facial Creme.